AUC

:   area under the curve

DAVID

:   Database for Annotation, Visualization and Integrated Discovery

DEG

:   differentially expressed gene

FDR

:   false discovery rate

GEO

:   Gene Expression Omnibus

GO

:   gene ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

MTI

:   miR--target interaction

qRT‐PCR

:   quantitative real‐time polymerase chain reaction

ROC

:   receiver operating characteristic

STAD

:   stomach adenocarcinoma

TCGA

:   The Cancer Genome Atlas

Stomach carcinoma is a leading cause of cancer death [1](#feb412365-bib-0001){ref-type="ref"}. Stomach adenocarcinoma (STAD) is the most common form of malignant stomach carcinoma and generally affects older people (50--70 years of age) [2](#feb412365-bib-0002){ref-type="ref"}. According to the Lauren classification, there are two main types of STAD defined as the diffuse type and the intestinal type. Some risk factors are involved in STAD including smoking, high‐salt diet, chronic gastritis and *Helicobacter pylori* infection [3](#feb412365-bib-0003){ref-type="ref"}. Up to now, the principal treatment of STAD has been gastrectomy accompanied by chemotherapy and radiation therapy. Despite advances in the treatment of STAD, the 5‐year survival rate is 5--15% [4](#feb412365-bib-0004){ref-type="ref"}. Therefore, understanding the pathogenesis of STAD and searching for new therapeutic targets of STAD are urgent issues.

Recently, several studies have improved our understanding of the molecular mechanisms and signaling pathways underlying tumorigenesis in STAD. For example, some tyrosine kinase receptors, including ERBB2, EGFR, FGFR2 and MET, are activated, which leads to tumorigenesis in STAD [5](#feb412365-bib-0005){ref-type="ref"}. Moreover, the phosphoinositide‐3‐kinase--Akt signaling pathway is activated and results in aggressive proliferation of STAD tumors [6](#feb412365-bib-0006){ref-type="ref"}, [7](#feb412365-bib-0007){ref-type="ref"}, [8](#feb412365-bib-0008){ref-type="ref"}.

The Cancer Genome Atlas (TCGA) database is an application platform for genome analysis consisting of large‐sample genome sequencing data analysis for 33 types of cancers, including STAD [9](#feb412365-bib-0009){ref-type="ref"}. miRNAs function as post‐transcriptional regulators that can repress translation or promote degradation or cleavage of complementary target mRNA sequences [10](#feb412365-bib-0010){ref-type="ref"}, and moreover, miRNAs have emerged as key players in the pathogenesis of STAD [11](#feb412365-bib-0011){ref-type="ref"}. In this study, we downloaded the miRNA and mRNA data for STAD from TCGA database and identified several differentially expressed miRNAs and a number of differentially expressed genes (DEGs). Then, we obtained the target genes of these differentially expressed miRNAs and analyzed their biological function. We used the quantitative real‐time polymerase chain reaction (qRT‐PCR) method to validate some bioinformatics analysis results. The Gene Expression Omnibus (GEO) was used to verify the expression of selected miRNAs and target genes. Finally, the diagnostic value of the identified miRNAs and genes was accessed by receiver operating characteristic (ROC) analysis. These findings may enable us to understand the progression and development of STAD.

Materials and methods {#feb412365-sec-0002}
=====================

Identification of differentially expressed miRNAs and genes {#feb412365-sec-0003}
-----------------------------------------------------------

From TCGA database (<http://cancergenome.nih.gov>), we downloaded miRNA (IlluminaHiSeq_miRNASeq) data of 84 samples (42 case samples and 42 normal samples) and mRNA (IlluminaHiSeq_RNASeqV2) data of 64 samples including 32 cases and 32 normal samples. Differential expression between normal and case samples was assessed using the R‐bioconductor package [deseq]{.smallcaps} 2, and the *P*‐value was calculated. Multiple hypothesis testing was performed via the Benjamini--Hochberg procedure. Differentially expressed miRNAs were screened with the threshold of the false discovery rate (FDR) \< 0.001, log2 fold change \> 2 and mean base \> 100. The DEGs were screened with the threshold of FDR \< 0.001 and absolute value of log2 fold change \> 2.

Target gene detection of differentially expressed miRNAs {#feb412365-sec-0004}
--------------------------------------------------------

Six miRNA‐target prediction tools including [rna]{.smallcaps}22 (<https://cm.jefferson.edu/rna22v2.0/>), [miranda]{.smallcaps} (<http://www.microrna.org/>), [mirdb]{.smallcaps} (<http://mirdb.org/miRDB/>), [mirwalk]{.smallcaps} (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html>), [pictar]{.smallcaps}2 (<http://pictar.mdc-berlin.de/>) and [targetscan]{.smallcaps} (<http://www.targetscan.org/>) were utilized to predict target genes of differentially expressed miRNAs. Target genes predicted by more than four algorithms or verified by experiments provided by the miRWalk database were screened out. Finally, the regulatory network between differentially expressed miRNAs and target genes was established, which was visualized using [cytoscape]{.smallcaps} software [12](#feb412365-bib-0012){ref-type="ref"}.

Functional annotation of target genes {#feb412365-sec-0005}
-------------------------------------

To further investigate the biological function, all DEGs and target genes of differentially expressed miRNAs were analyzed in the context of several databases such as Gene Ontology (GO) functional categories and the Kyoto Encyclopedia of Genes and Genomes (KEGG) biochemical pathway using the Database for Annotation, Visualization and Integrated Discovery (DAVID).

qRT‐PCR validation {#feb412365-sec-0006}
------------------

Among the identified differentially expressed miRNAs and their target genes, we selected miRNAs and genes with expression significance for and association with STAD. Depending on this criterion, hsa‐miR‐139‐5p, hsa‐miR‐145‐3p, hsa‐miR‐145‐5p, hsa‐miR‐490‐3p and their target genes *ADAM12*,*ACAN*,*HOXC11* and *MMP11* were selected for validation. Three tumor tissues and three para‐carcinoma tissues from participating individuals were obtained immediately after surgery. The collected tissues were frozen in liquid nitrogen for further RNA extraction. All participating individuals provided informed consent with the approval of the China‐Japan Friendship Hospital.

Total RNA of the tissue samples was extracted using the TRIzol^®^ Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s protocols. One microgram of RNA was applied to synthesize DNA by SuperScript^®^ III Reverse Transcriptase (Invitrogen). Then real‐time PCR was performed in an ABI 7500 real‐time PCR system with SYBR^®^ Green PCR Master Mix (Invitrogen). To confirm their reliability and validity, U6 and 18S rRNA were selected as the endogenous standards. All reactions were carried out in triplicate and relative gene expressions were analyzed by the 2^−ΔΔ*C*t^ method. The primer sequence is shown in Table [1](#feb412365-tbl-0001){ref-type="table-wrap"}.

###### 

The primer sequence in the qRT‐PCR

  Primer                               Sequence (5′ to 3′)
  ------------------------------------ -----------------------------------
  *ADAM12*                             Forward: AAGACCTTGATACGACTGCTGTTT
  Reverse: GACTGGGGCTGAGGGACATT        
  *ACAN*                               Forward: GTCACACCTGAGCAGCATCGT
  Reverse: CTGGTAGTCTTGGGCATTGTTGT     
  *HOXC11*                             Forward: GGCTGAGGAGGAGAACACAAATC
  Reverse: GCCGCTTCTCTTTGTTGATATACAC   
  *MMP11*                              Forward: CCCGCAACCGACAGAAGAG
  Reverse: GGCGTCACATCGCTCCATAC        
  18S rRNA                             Forward: GTAACCCGTTGAACCCCATT
  Reverse: CCATCCAATCGGTAGTAGCG        
  hsa‐miR‐139‐5p                       Forward: TCTACAGTGCACGTGTCTCCAGT
  hsa‐miR‐145‐3p                       Forward: GGATTCCTGGAAATACTGTTCT
  hsa‐miR‐145‐5p                       Forward: GTCCAGTTTTCCCAGGAATC
  hsa‐miR‐490‐3p                       Forward: CAACCTGGAGGACTCCATGCT
  U6                                   Forward: CTCGCTTCGGCAGCACA
  Reverse: AACGCTTCACGAATTTGCGT        
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Validation of the expression of miRNAs and target genes by GEO {#feb412365-sec-0007}
--------------------------------------------------------------

The GEO (<http://www.ncbi.nlm.nih.gov/geo>) database was used to validate the expression of selected miRNAs and targeted genes. We compared the expression levels of miRNAs and targeted genes between STAD cases and adjacent non‐tumor controls and the difference of expression levels were displayed as box‐plots.

ROC analyses {#feb412365-sec-0008}
------------

Using the [proc]{.smallcaps} package in the R language we, performed the ROC analyses to assess the diagnostic value of selected miRNAs and target genes. The area under the curve (AUC) under binomial exact confidence interval was calculated and the ROC curve was generated.

Results {#feb412365-sec-0009}
=======

Differentially expressed miRNAs and genes {#feb412365-sec-0010}
-----------------------------------------

In this study, we found that nine miRNAs (three up‐regulated and six down‐regulated) and 1248 genes (371 up‐regulated and 877 down‐regulated) were differentially expressed in STAD. Table [2](#feb412365-tbl-0002){ref-type="table-wrap"} shows all differentially expressed miRNAs (precursor form) including hsa‐mir‐139, hsa‐mir‐196a‐1, hsa‐mir‐196b, hsa‐mir‐133a‐1, hsa‐mir‐1‐2, hsa‐mir‐145, hsa‐mir‐135b, hsa‐mir‐133b and hsa‐mir‐490. The top 20 DEGs are listed in Table [3](#feb412365-tbl-0003){ref-type="table-wrap"}. Additionally, heat maps of these differentially expressed precursor form of miRNAs and genes are shown in Figs [1](#feb412365-fig-0001){ref-type="fig"} and [2](#feb412365-fig-0002){ref-type="fig"}, respectively.

###### 

The differentially expressed precursor form of miRNAs in STAD

  miRNA            Mean base   Log2 fold change   Standard error   Wald statistic   *P*              *P* adj          Up/down
  ---------------- ----------- ------------------ ---------------- ---------------- ---------------- ---------------- ---------
  hsa‐mir‐139      528.1534    −2.55383           0.202603         −12.6051         1.98 × 10^−36^   3.51 × 10^−34^   Down
  hsa‐mir‐196a‐1   392.8496    4.36323            0.345863         12.6155          1.73 × 10^−36^   3.51 × 10^−34^   Up
  hsa‐mir‐196b     1049.324    4.091521           0.342584         11.94312         7.05 × 10^−33^   8.35 × 10^−31^   Up
  hsa‐mir‐133a‐1   900.0538    −3.34948           0.30633          −10.9342         7.91 × 10^−28^   7.02 × 10^−26^   Down
  hsa‐mir‐1‐2      1498.213    −3.23485           0.331376         −9.76188         1.64 × 10^−22^   8.32 × 10^−21^   Down
  hsa‐mir‐145      48448.02    −2.37286           0.249126         −9.52473         1.65 × 10^−21^   7.34 × 10^−20^   Down
  hsa‐mir‐135b     127.1043    2.927057           0.315644         9.273278         1.81 × 10^−20^   6.41 × 10^−19^   Up
  hsa‐mir‐133b     127.2602    −2.76184           0.307681         −8.97632         2.80 × 10^−19^   8.28 × 10^−18^   Down
  hsa‐mir‐490      255.5693    −3.83958           0.488705         −7.85665         3.95 × 10^−15^   7.37 × 10^−14^   Down
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###### 

Top 20 DEGs in STAD

  mRNA                Mean base   Log2 fold change   Standard error   Wald statistic   *P*              FDR              Up/down
  ------------------- ----------- ------------------ ---------------- ---------------- ---------------- ---------------- ---------
  CST1\|1469          1950.411    7.706956           0.456963         16.86562         8.06 × 10^−64^   1.56 × 10^−59^   Up
  COL10A1\|1300       628.3591    6.468628           0.398018         16.25211         2.16 × 10^−59^   2.09 × 10^−55^   Up
  ESM1\|11082         164.0381    4.772024           0.307322         15.52774         2.25 × 10^−54^   1.45 × 10^−50^   Up
  GABRD\|2563         54.36653    3.639088           0.279383         13.02546         8.77 × 10^−39^   4.24 × 10^−35^   Up
  HOXC10\|3226        356.3751    6.328307           0.500079         12.65462         1.05 × 10^−36^   4.08 × 10^−33^   Up
  COL11A1\|1301       372.4826    5.984012           0.488973         12.23792         1.95 × 10^−34^   6.28 × 10^−31^   Up
  MMP11\|4320         2090.436    3.807886           0.314897         12.09247         1.16 × 10^−33^   3.20 × 10^−30^   Up
  LYVE1\|10894        921.3208    −3.57139           0.304514         −11.7282         9.14 × 10^−32^   2.21 × 10^−28^   Down
  HOTAIR\|100124700   45.54065    5.787221           0.502089         11.52628         9.73 × 10^−31^   2.09 × 10^−27^   Up
  CTHRC1\|115908      845.8077    3.275777           0.284703         11.50593         1.23 × 10^−30^   2.38 × 10^−27^   Up
  LRFN4\|78999        1583.359    2.39677            0.211807         11.3158          1.10 × 10^−29^   1.93 × 10^−26^   Up
  C1QTNF6\|114904     519.9666    2.003764           0.177663         11.27842         1.68 × 10^−29^   2.70 × 10^−26^   Up
  PIWIL1\|9271        134.2764    6.952432           0.621324         11.18971         4.58 × 10^−29^   6.81 × 10^−26^   Up
  SH3GL2\|6456        62.35987    −4.47119           0.407905         −10.9613         5.86 × 10^−28^   8.09 × 10^−25^   Down
  CILP2\|148113       126.4808    3.88935            0.356923         10.89688         1.19 × 10^−27^   1.54 × 10^−24^   Up
  HOXC11\|3227        157.2612    4.742368           0.449461         10.55122         5.01 × 10^−26^   6.06 × 10^−23^   Up
  STRA6\|64220        295.6888    4.633958           0.439962         10.53262         6.11 × 10^−26^   6.95 × 10^−23^   Up
  ALPP\|250           75.03801    6.927139           0.658164         10.52494         6.63 × 10^−26^   7.12 × 10^−23^   Up
  CELSR3\|1951        616.3266    2.799618           0.267519         10.46512         1.25 × 10^−25^   1.27 × 10^−22^   Up
  MAPK15\|225689      58.32309    3.731925           0.358736         10.40299         2.40 × 10^−25^   2.32 × 10^−22^   Up
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![Heat map of differentially expressed precursor form of miRNAs in STAD.](FEB4-8-279-g001){#feb412365-fig-0001}

![Heat map of top 100 differentially expressed genes in STAD.](FEB4-8-279-g002){#feb412365-fig-0002}

Identification of miRNA--target interactions {#feb412365-sec-0011}
--------------------------------------------

In the present study, potential target genes of the differentially expressed precursor form of miRNAs were identified. We found 160 target genes with 270 miRNA--target pairs including 189 interaction pairs with miRNA up‐regulated and target genes down‐regulated and 81 interaction pairs with miRNA down‐regulated and target genes up‐regulated in STAD subjects. The established regulatory network of miRNA--targets is showed in Fig. [3](#feb412365-fig-0003){ref-type="fig"}. In addition, we further confirmed all of the miR--target interactions (MTIs) in TCGA data analysis using miRTarBAse. Our results showed that there was a total of 46 MTIs after the miRTarBAse analysis. However, we obtained a total of 187 MTIs by using the miRWalk database. Therefore, the MTIs in the miRWalk database were more than those in the miRTarBAse database. Taking the intersection of the miRTarBAse and miRWalk databases, a total of 22 common MTIs was identified. The original MTIs from the miRWalk and miRTarBAse databases are listed in Tables [S1](#feb412365-sup-0002){ref-type="supplementary-material"} and [S2](#feb412365-sup-0003){ref-type="supplementary-material"}, respectively. A Venn diagram of MTIs in the groups of the miRTarBAse database *vs* the miRWalk database is shown in Fig. [S1](#feb412365-sup-0001){ref-type="supplementary-material"}.

![Regulatory network of precursor form of miRNAs and target genes in STAD. Rhombus and oval represent miRNA and target gene, respectively. Red and green colors represent up‐regulation and down‐regulation, respectively. The full blue lines indicate the miRNA--mRNA validation pairs and the dashed lines indicate the miRNA--mRNA prediction pairs.](FEB4-8-279-g003){#feb412365-fig-0003}

Target genes enrichment analysis {#feb412365-sec-0012}
--------------------------------

Based on the DAVID database, we analyzed the biological function and pathways of these 160 target genes. Additionally, we also analyzed the function of all DEGs by KEGG. The enrichment of GO functional categories and KEGG biochemical pathways showed that these target genes were significantly enriched in calcium‐transporting ATPase activity (FDR = 0.001048), calmodulin binding (FDR = 0.002055), calcium signaling pathway (FDR = 7.97 × 10^−6^), salivary secretion (FDR = 9.13 × 10^−5^), pancreatic secretion (FDR = 0.00209), neuroactive ligand--receptor interaction (FDR = 0.004133), cell adhesion molecules (FDR = 0.003932), bile secretion (FDR = 0.003801) and vascular smooth muscle contraction (FDR = 0.018674). A GO analysis of these enriched target genes is shown in Table [4](#feb412365-tbl-0004){ref-type="table-wrap"}, a KEGG pathway analysis of these target genes is listed in Table [5](#feb412365-tbl-0005){ref-type="table-wrap"} and the pathway maps in KEGG of calcium signaling pathway and bile secretion are shown in Figs [4](#feb412365-fig-0004){ref-type="fig"} and [5](#feb412365-fig-0005){ref-type="fig"}, which are related to STAD. Interestingly, all DEGs were found to be enriched in the signal pathway of gastric acid secretion (Fig. [6](#feb412365-fig-0006){ref-type="fig"}), which also plays a role in STAD.

###### 

GO function analysis of target genes

  Item                 Item details                                                      Count   *P*              FDR              Genes
  -------------------- ----------------------------------------------------------------- ------- ---------------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Molecular function                                                                                                               
  GO:0046872           Metal ion binding                                                 37      3.36 × 10^−9^    9.76 × 10^−7^    *ADCY2*,*MAT1A*,*MMP11*,*ALOX12*,*ATP2B3*,*TRIM72*,*XPNPEP2*,*MMP8*,*TRIM71*,*ATP2B4*,*ZNF469*,*EME1*,*KCNMA1*,*HMGCLL1*,*ADAMTS12*,*ADAM12*,*STK32A*,*NPTX1*,*ENPP3*,*FOXP2*,*NRXN3*,*PRUNE2*,*NOS1*,*MCM10*,*ALPPL2*,*ATP2B2*,*ZNF695*,*PGR*,*USP2*,*AR*,*NR4A3*,*ADAMTS2*,*ZNF385B*,*MSRB3*,*MFI2*,*MEX3A*,*RELN*
  GO:0005388           Calcium‐transporting ATPase activity                              3       7.23 × 10^−6^    0.001048         *ATP2B3*,*ATP2B4*,*ATP2B2*
  GO:0043565           Sequence‐specific DNA binding (MF)                                11      3.46 × 10^−5^    0.002009         *HLF*,*HOXA9*,*SIX3*,*HOXB9*,*FOXP2*,*HOXC11*,*POU4F1*,*PGR*,*TOP2A*,*AR*,*NR4A3*
  GO:0005516           Calmodulin binding                                                6       5.67 × 10^−5^    0.002055         *ATP2B3*,*ATP2B4*,*CALD1*,*NOS1*,*ATP2B2*,*SLC8A2*
  GO:0017022           Myosin binding                                                    3       4.71 × 10^−5^    0.002275         *SLC6A4*,*CALD1*,*SNAP25*
  GO:0005216           Ion channel activity                                              7       3.15 × 10^−5^    0.002282         *GRIK3*,*KCNMA1*,*KCNQ5*,*GRIA4*,*GABRG1*,*CHRNA4*,*KCNA2*
  GO:0005515           Protein binding                                                   38      5.65 × 10^−5^    0.002341         *CLSPN*,*DTNA*,*ACAN*,*ALOX12*,*HMGA2*,*SLC6A4*,*CELSR3*,*HOXA9*,*ATP2B4*,*HOXB9*,*EME1*,*KCNMA1*,*NTNG1*,*ADAM12*,*SORCS1*,*MYOCD*,*NEGR1*,*APOA1*,*MC2R*,*FRMPD4*,*CDC6*,*PLN*,*CASR*,*NOS1*,*MCM10*,*MAL*,*ZNF365*,*ATP2B2*,*PGR*,*TOP2A*,*USP2*,*AR*,*NEFM*,*MFI2*,*DLG2*,*KRT7*,*CDK6*,*SNAP25*
  GO:0017075           Syntaxin‐1 binding                                                3       2.43 × 10^−5^    0.002347         *SLC6A4*,*CPLX2*,*SNAP25*
  GO:0004872           Receptor activity                                                 19      7.64 × 10^−5^    0.002463         *CELSR3*,*HTR2C*,*HAVCR1*,*GRIK3*,*GPR158*,*MC2R*,*GRIA4*,*NMBR*,*NRXN3*,*CASR*,*EPHA7*,*TNFRSF11B*,*PGR*,*CHRNA4*,*AR*,*NR4A3*,*STAB 2*,*IGSF11*,*NLGN1*
  GO:0004222           Metalloendopeptidase activity                                     5       0.000108         0.00313          *MMP11*,*MMP8*,*ADAMTS12*,*ADAM12*,*ADAMTS2*
  GO:0019899           Enzyme binding                                                    6       0.000216         0.005705         *APOA1*,*PGR*,*TOP2A*,*PRIMA1*,*AR*,*AKAP6*
  GO:0005249           Voltage‐gated potassium channel activity                          4       0.000312         0.006971         *KCNMA1*,*KCNQ5*,*SNAP25*,*KCNA2*
  GO:0005372           Water transmembrane transporter activity                          2       0.000295         0.00712          *AQP2*,*AQP4*
  GO:0005244           Voltage‐gated ion channel activity                                5       0.000589         0.011389         *CACNA1H*,*KCNMA1*,*KCNQ5*,*KCNA1*,*KCNA2*
  GO:0030165           PDZ domain binding                                                4       0.000562         0.011646         *ATP2B4*,*AQP2*,*ATP2B2*,*DLG2*
  Biological process                                                                                                               
  GO:0007268           Synaptic transmission                                             16      2.12 × 10^−11^   1.60 × 10^−8^    *ADCY2*,*DTNA*,*HTR2C*,*GRIK3*,*TAC1*,*KCNMA1*,*KCNQ5*,*GRIA4*,*NPTX1*,*GABRG1*,*CHRNA4*,*DLG2*,*KCNA1*,*SLC5A7*,*SNAP25*,*KCNA2*
  GO:0055085           Transmembrane transport                                           18      5.43 × 10^−10^   2.04 × 10^−7^    *ADCY2*,*ATP2B3*,*CACNA1H*,*ATP2B4*,*KCNMA1*,*KCNQ5*,*SLC6A15*,*SLC9A4*,*APOA1*,*SLCO1A2*,*AQP2*,*ATP2B2*,*AQP4*,*SLC8A2*,*KCNA1*,*SLC5A7*,*GPR155*,*KCNA2*
  GO:0006811           Ion transport                                                     15      2.91 × 10^−8^    7.29 × 10^−6^    *CACNA1H*,*GRIK3*,*KCNMA1*,*KCNQ5*,*SLC6A15*,*SLC9A4*,*GRIA4*,*GABRG1*,*SLCO1A2*,*CHRNA4*,*MFI2*,*SLC8A2*,*KCNA1*,*SLC5A7*,*KCNA2*
  GO:0007275           Multicellular organismal development                              19      5.17 × 10^−8^    9.73 × 10^−6^    *HLF*,*MMP11*,*HMGA2*,*CELSR3*,*HOXA9*,*SIX3*,*TRIM71*,*HOXB9*,*NTNG1*,*ARC*,*HOXC11*,*FIGF*,*NDRG4*,*EPHA7*,*POU4F1*,*GPM6B*,*ST6GAL2*,*RELN*,*BMP3*
  GO:0007155           Cell adhesion                                                     13      1.45 × 10^−6^    0.000218         *OPCML*,*ACAN*,*CELSR3*,*ADAM12*,*NEGR1*,*CADM3*,*NRXN3*,*AOC3*,*STAB 2*,*IGSF11*,*CNTN2*,*RELN*,*NLGN1*
  GO:0030168           Platelet activation                                               8       1.12 × 10^−5^    0.001409         *ATP2B3*,*ATP2B4*,*KCNMA1*,*APOA1*,*FIGF*,*NOS1*,*ATP2B2*,*SLC8A2*
  GO:0007520           Myoblast fusion                                                   3       1.41 × 10^−5^    0.001517         *CACNA1H*,*ADAM12*,*NOS1*
  GO:0060748           Tertiary branching involved in mammary gland duct morphogenesis   2       5.94 × 10^−5^    0.005596         *PGR*,*AR*
  GO:0030574           Collagen catabolic process                                        3       9.46 × 10^−5^    0.007122         *MMP11*,*MMP8*,*ADAMTS2*
  GO:0006810           Transport                                                         11      9.25 × 10^−5^    0.007743         *ATP2B3*,*CACNA1H*,*TRIM72*,*ATP2B4*,*GRIA4*,*NPTX1*,*SLC35F1*,*ATP2B2*,*AQP4*,*AR*,*ABCA9*
  GO:0007420           Brain development                                                 6       0.000161         0.011038         *CKB*,*SLC6A4*,*SIX3*,*EPHA7*,*ATP2B2*,*RELN*
  GO:0001503           Ossification                                                      4       0.000198         0.011493         *ACAN*,*MMP8*,*CASR*,*BMP3*
  GO:0051346           Negative regulation of hydrolase activity                         2       0.000197         0.012361         *APOA1*,*NOS1*
  GO:0030879           Mammary gland development                                         3       0.000265         0.01329          *HOXA9*,*HOXB9*,*PGR*
  GO:0042391           Regulation of membrane potential                                  3       0.000265         0.01329          *GRIK3*,*KCNMA1*,*CHRNA4*
  Cellular component                                                                                                               
  GO:0005886           Plasma membrane                                                   57      1.47 × 10^−18^   2.16 × 10^−16^   *ADCY2*,*OPCML*,*DTNA*,*ATP2B3*,*FAM129A*,*SLC6A4*,*NBEA*,*CELSR3*,*HTR2C*,*XPNPEP2*,*GBP5*,*GRIK3*,*ATP2B4*,*PPP1R12B*,*TAC1*,*KCNMA1*,*KCNQ5*,*NTNG1*,*ACSL6*,*SLC6A15*,*SLC9A4*,*GPR158*,*ARC*,*ADAM12*,*NEGR1*,*CADM3*,*APOA1*,*MC2R*,*GRIA4*,*NMBR*,*CALD1*,*PMEPA1*,*CASR*,*EPHA7*,*ALPPL2*,*GABRG1*,*SLCO1A2*,*AQP2*,*ATP2B2*,*AOC3*,*PRIMA1*,*AQP4*,*CHRNA4*,*TUB*,*STAB 2*,*MFI2*,*IGSF11*,*GJB7*,*DLG2*,*SLC8A2*,*CNTN2*,*KCNA1*,*CAP2*,*SLC5A7*,*SNAP25*,*NLGN1*,*KCNA2*
  GO:0030425           Dendrite                                                          12      4.11 × 10^−11^   3.02 × 10^−9^    *ADCY2*,*GRIK3*,*NEGR1*,*GRIA4*,*CPLX2*,*EPHA7*,*ATP2B2*,*CHRNA4*,*AR*,*DLG2*,*RELN*,*NLGN1*
  GO:0016021           Integral to membrane                                              50      1.70 × 10^−10^   8.34 × 10^−9^    *ADCY2*,*ATP2B3*,*CACNA1H*,*CELSR3*,*HTR2C*,*ELFN2*,*HAVCR1*,*GRIK3*,*KCNMA1*,*KCNQ5*,*ACSL6*,*SLC6A15*,*SLC9A4*,*GPR158*,*ADAM12*,*SORCS1*,*CADM3*,*GRIA4*,*PMEPA1*,*NRXN3*,*PLN*,*CASR*,*SLC35F1*,*GABRG1*,*SLCO1A2*,*AQP2*,*WSCD2*,*ATP2B2*,*TMEM74*,*AOC3*,*PRIMA1*,*ATRNL1*,*AQP4*,*CHRNA4*,*RIC3*,*GPM6B*,*ST8SIA3*,*RDH16*,*ST6GAL2*,*HS6ST3*,*IGSF11*,*GJB7*,*SLC8A2*,*KCNA1*,*ABCA9*,*SLC5A7*,*TMEM236*,*GPR155*,*KCNA2*,*TMEM196*
  GO:0043025           Neuronal cell body                                                12      3.15 × 10^−10^   1.16 × 10^−8^    *TAC1*,*NEGR1*,*GRIA4*,*CALD1*,*CPLX2*,*EPHA7*,*ATP2B2*,*CHRNA4*,*DLG2*,*SLC8A2*,*CNTN2*,*SNAP25*
  GO:0045202           Synapse                                                           12      7.76 × 10^−9^    2.28 × 10^−7^    *DTNA*,*GRIK3*,*ARC*,*GRIA4*,*CPLX2*,*NOS1*,*GABRG1*,*PRIMA1*,*CHRNA4*,*DLG2*,*SNAP25*,*NLGN1*
  GO:0044224           Juxtaparanode region of axon                                      4       2.66 × 10^−8^    6.51 × 10^−7^    *DLG2*,*CNTN2*,*KCNA1*,*KCNA2*
  GO:0045211           Postsynaptic membrane                                             8       1.06 × 10^−6^    2.22 × 10^−5^    *GRIK3*,*ARC*,*GRIA4*,*EPHA7*,*GABRG1*,*CHRNA4*,*DLG2*,*NLGN1*
  GO:0008076           Voltage‐gated potassium channel complex                           6       3.53 × 10^−6^    5.77 × 10^−5^    *KCNMA1*,*KCNQ5*,*CNTN2*,*KCNA1*,*SNAP25*,*KCNA2*
  GO:0005887           Integral to plasma membrane                                       17      3.34 × 10^−6^    6.14 × 10^−5^    *OPCML*,*SLC6A4*,*GRIK3*,*ATP2B4*,*SLC6A15*,*MC2R*,*NMBR*,*ENPP3*,*NRXN3*,*CASR*,*EPHA7*,*MAL*,*AQP4*,*STAB 2*,*MFI2*,*CNTN2*,*NLGN1*
  GO:0016020           Membrane                                                          38      6.88 × 10^−6^    0.000101         *ADCY2*,*CACNA1H*,*XPNPEP2*,*ELFN2*,*HAVCR1*,*KCNMA1*,*KCNQ5*,*SLC6A15*,*SORCS1*,*ENPP3*,*FIGF*,*NRXN3*,*PLN*,*SLC35F1*,*ALPPL2*,*SLCO1A2*,*AQP2*,*WSCD2*,*MAL*,*ATP2B2*,*TMEM74*,*ATRNL1*,*AQP4*,*CHRNA4*,*RIC3*,*GPM6B*,*ST8SIA3*,*RDH16*,*AKAP6*,*ST6GAL2*,*HS6ST3*,*SLC8A2*,*ABCA9*,*SLC5A7*,*TMEM236*,*GPR155*,*KCNA2*,*TMEM196*
  GO:0030054           Cell junction                                                     11      1.05 × 10^−5^    0.00014          *DTNA*,*GRIK3*,*ARC*,*GRIA4*,*GABRG1*,*PRIMA1*,*CHRNA4*,*GJB7*,*DLG2*,*SNAP25*,*NLGN1*
  GO:0031225           Anchored to membrane                                              6       1.17 × 10^−5^    0.000144         *OPCML*,*XPNPEP2*,*NEGR1*,*ALPPL2*,*MFI2*,*CNTN2*
  GO:0043197           Dendritic spine                                                   5       1.50 × 10^−5^    0.000169         *ARC*,*FRMPD4*,*CALD1*,*NOS1*,*SLC8A2*
  GO:0005578           Proteinaceous extracellular matrix                                7       4.58 × 10^−5^    0.000481         *ACAN*,*MMP11*,*MMP8*,*ADAMTS12*,*TNFRSF11B*,*ADAMTS2*,*RELN*
  GO:0005737           Cytoplasm                                                         43      4.99 × 10^−5^    0.000489         *ADCY2*,*DTNA*,*CKB*,*KIAA1199*,*ALOX12*,*FAM129A*,*NBEA*,*HTR2C*,*HOXA9*,*TRIM71*,*PPP1R12B*,*BAAT*,*ARC*,*NMBR*,*CALD1*,*CDC6*,*FOXP2*,*HOXC11*,*NDRG4*,*SYNPO2*,*CPLX2*,*PRUNE2*,*NOS1*,*MCM10*,*AQP2*,*ZNF365*,*ATP2B2*,*PGR*,*TOP2A*,*AQP4*,*USP2*,*AR*,*TUB*,*PAK7*,*AKAP6*,*STAB 2*,*DLG2*,*MEX3A*,*KRT7*,*CDK6*,*SNAP25*,*RELN*,*KLHL4*

John Wiley & Sons, Ltd

###### 

The KEGG pathway analysis of target genes

  Item         Item details                               Count   *P*             FDR             Genes
  ------------ ------------------------------------------ ------- --------------- --------------- ----------------------------------------------------------------------------
  Kegg:04020   Calcium signaling pathway                  9       1.03 × 10^−7^   7.97 × 10^−6^   *SLC8A2*,*ADCY2*,*ATP2B4*,*CACNA1H*,*HTR2C*,*ATP2B2*,*PLN*,*NOS1*,*ATP2B3*
  Kegg:04970   Salivary secretion                         6       2.37 × 10^−6^   9.13 × 10^−5^   *ADCY2*,*KCNMA1*,*ATP2B4*,*ATP2B2*,*NOS1*,*ATP2B3*
  Kegg:04972   Pancreatic secretion                       5       8.14 × 10^−5^   0.00209         *ADCY2*,*KCNMA1*,*ATP2B4*,*ATP2B2*,*ATP2B3*
  Kegg:04080   Neuroactive ligand--receptor interaction   7       0.000215        0.004133        *NMBR*,*MC2R*,*HTR2C*,*GABRG1*,*GRIK3*,*GRIA4*,*CHRNA4*
  Kegg:04514   Cell adhesion molecules                    5       0.000255        0.003932        *NRXN3*,*CNTN2*,*NLGN1*,*CADM3*,*NEGR1*
  Kegg:04976   Bile secretion                             4       0.000296        0.003801        *ADCY2*,*AQP4*,*SLCO1A2*,*BAAT*
  Kegg:04270   Vascular smooth muscle contraction         4       0.001698        0.018674        *ADCY2*,*KCNMA1*,*CALD1*,*PPP1R12B*

John Wiley & Sons, Ltd

![Target genes that were significantly enriched in calcium signaling pathway. The red rectangles represent the target genes that are enriched in calcium signaling pathway. The figure was obtained by the Kanehisa Laboratories.](FEB4-8-279-g004){#feb412365-fig-0004}

![Target genes that were significantly enriched in bile secretion. The red rectangles were represented the target genes that are enriched in bile secretion. The figure was obtained by the Kanehisa Laboratories.](FEB4-8-279-g005){#feb412365-fig-0005}

![Target genes that were significantly enriched in gastric acid secretion. The red rectangles represent the target genes that are enriched in gastric acid secretion. The figure was obtained by the Kanehisa Laboratories.](FEB4-8-279-g006){#feb412365-fig-0006}

qRT‐PCR verification of selected miRNA and genes {#feb412365-sec-0013}
------------------------------------------------

To confirm the validity and reliability of bioinformatics results, we selected and assessed the expression levels of four key mature forms of miRNAs (hsa‐miR‐139‐5p, hsa‐miR‐145‐3p, hsa‐miR‐145‐5p and hsa‐miR‐490‐3p) and their target genes including *ADAM12*,*ACAN*,*HOXC11* and *MMP11* (Fig. [7](#feb412365-fig-0007){ref-type="fig"}). The results showed that hsa‐miR‐145‐3p, hsa‐miR‐145‐5p and hsa‐miR‐490‐3p showed down‐regulation, and their target genes (*ADAM12*,*ACAN*,*HOXC11* and *MMP11*) showed up‐regulation, consistent with the bioinformatics results. However, the expression of hsa‐miR‐139‐5p was inconsistent with the bioinformatics result.

![Validation of differentially expressed mature forms of miRNAs and mRNAs in the STAD tissues by qRT‐PCR. \*\**P* \< 0.01.](FEB4-8-279-g007){#feb412365-fig-0007}

Validation the expression of miRNAs and target genes {#feb412365-sec-0014}
----------------------------------------------------

In this study, two down‐regulated miRNAs (hsa‐miR‐145‐3p and hsa‐miR‐145‐5p) and four up‐regulated target genes (*ADAM12*,*ACAN*,*HOXC11* and *MMP11*) in STAD were selected to perform the expression validation (Fig. [8](#feb412365-fig-0008){ref-type="fig"}). Different expression levels of them between STAD and non‐tumor tissues were analyzed and depicted through box‐plots. These box‐plots were displayed visually by median and interquartile range. The expression levels of hsa‐miR‐145‐3p and hsa‐miR‐145‐5p were significantly down‐regulated in the case group compared with the normal group and the expression of *ADAM12*,*ACAN*,*HOXC11* and *MMP11* was significantly up‐regulated in the case group compared with the normal group. Compared with the normal group, the expression levels for the case group were consistent with our bioinformatics analysis.

![Validation of the expression levels of selected miRNAs and in STAD based on GEO database. The *x*‐axis shows the case and normal groups and the *y*‐axis shows expression read counts. Case group and normal group indicate STAD tissues and adjacent non‐tumor tissues.](FEB4-8-279-g008){#feb412365-fig-0008}

ROC curve analysis {#feb412365-sec-0015}
------------------

We performed ROC curve analyses and calculated the AUC to assess the discriminatory ability of two selected miRNAs (hsa‐miR‐139‐5p and hsa‐miR‐145‐3p) and one target gene (*MMP11*) from the GEO dataset (Fig. [9](#feb412365-fig-0009){ref-type="fig"}). The AUC for them was more than 0.7. *MMP11* had the largest AUC. For STAD diagnosis, the 1 -- specificity (proportion of false positives) and sensitivity (proportion of true positives) of hsa‐miR‐139‐5p were 87.5% and 71.7%, respectively; the 1 -- specificity (proportion of false positives) and sensitivity (proportion of true positives) of hsa‐miR‐145‐3p were 100% and 56.7%, respectively; the 1 -- specificity (proportion of false positives) and sensitivity (proportion of true positives) of *MMP11* were 100% and 83.3%, respectively.

![ROC curves of selected miRNAs and target genes between STAD patients and healthy controls. The ROC curves were used to show the diagnostic ability of these selected miRNAs and target genes with 1 -- specificity (the proportion of false positives) and sensitivity (the proportion of true positives). The *x*‐axis shows 1 -- specificity and the *y*‐axis shows sensitivity.](FEB4-8-279-g009){#feb412365-fig-0009}

Discussion {#feb412365-sec-0016}
==========

STAD remains the second leading cause of cancer death and makes up approximately 10% of newly diagnosed cancers [13](#feb412365-bib-0013){ref-type="ref"}. Therefore, an understanding of the molecular mechanism of STAD is needed. In the current study, we obtained nine differentially expressed miRNAs and 1248 DEGs for STAD. Additionally, target gene detection revealed 160 target genes of these differentially expressed miRNAs. After biological function analysis, we found that these target genes were most significantly enriched in the calcium signaling pathway and bile secretion.

Calcium signals can regulate the majority of physiological processes ranging from cell proliferation to cell apoptosis [14](#feb412365-bib-0014){ref-type="ref"}. It is reported that any disorders of Ca^2+^ channels and/or receptors will lead to various diseases, such as cancer [15](#feb412365-bib-0015){ref-type="ref"}. In this study, we found that the target genes (*SLC8A2*,*ADCY2*,*ATP2B4*,*CACNA1H*,*HTR2C*,*ATP2B2*,*PLN*,*NOS1* and *ATP2B3*) of differentially expressed miRNAs were associated with the calcium signaling pathway, which suggested a role for calcium signaling in STAD.

It is pointed out that there is a positive relationship between bile acid concentration and gastric carcinoma development, which suggests a carcinogenic role of bile acid in gastritis [16](#feb412365-bib-0016){ref-type="ref"}. Furthermore, Suzuki *et al*. [17](#feb412365-bib-0017){ref-type="ref"} also found that patients with a high level of bile acid developed gastric carcinoma more frequently than those patients with a low bile acid level. In this study, we found that target genes (*ADCY2*,*AQP4*,*SLCO1A2* and *BAAT*) were related to bile secretion, which suggested a relationship between bile secretion and STAD.

All in all, these identified target genes played roles in the biological processes of calcium signaling and bile secretion in STAD. Additionally, we also investigated the function of all DEGs by KEGG pathway analysis and found that these DEGs were remarkably involved in signaling pathways of gastric acid secretion.

The principal secretory function of the stomach is secreting gastric acid [18](#feb412365-bib-0018){ref-type="ref"}. Gastric acid functions in a number of ways including modulating the gut microbiome, assisting in protein digestion and facilitating absorption of iron and calcium [19](#feb412365-bib-0019){ref-type="ref"}. It is reported that *H. pylori* is related to gastric carcinoma [20](#feb412365-bib-0020){ref-type="ref"}. Interestingly, it is found that in patients with relatives with gastric carcinoma, *H. pylori* infection is related to decreasing gastric acid secretion [21](#feb412365-bib-0021){ref-type="ref"}. In this study, we found all DEGs were significantly enriched in the signaling pathway of gastric acid secretion, which further demonstrated the role of gastric acid secretion in the development of STAD.

Among identified miRNAs, mature the form of hsa‐miR‐139‐5p, hsa‐miR‐145‐3p, hsa‐miR‐145‐5p and hsa‐miR‐490‐3p was validated by qRT‐PCR and the results were consistent with the bioinformatics results except for the expression of hsa‐miR‐139‐5p. The small sample size we used for qRT‐PCR may account for this inconsistency. It is pointed out that hsa‐miR‐139‐5p shows decreased expression associated with STAD [22](#feb412365-bib-0022){ref-type="ref"}, [23](#feb412365-bib-0023){ref-type="ref"}. Previous reports found that hsa‐miR‐145 was a potential tumor suppressor and hsa‐miR‐145‐3p and hsa‐miR‐145‐5p were down‐regulated in stomach carcinoma [24](#feb412365-bib-0024){ref-type="ref"}, [25](#feb412365-bib-0025){ref-type="ref"}, [26](#feb412365-bib-0026){ref-type="ref"}. Kuo *et al*. [22](#feb412365-bib-0022){ref-type="ref"} demonstrated that hsa‐miR‐490‐3p was down‐regulated in STAD gastric carcinoma tissues. In this study, our results were in agreement with previous reports, which further demonstrated the role of these differentially expressed miRNAs in the process of STAD. Significantly, both hsa‐miR‐139‐5p and hsa‐miR‐145‐3p had a potential diagnostic value for STAD.

Additionally, we also validated the target genes (*ADAM12*,*ACAN*,*HOXC11* and *MMP11*) of these four miRNAs mentioned above, and their expression patterns were consistent with the bioinformatics results. ADAM12 is a complicated and multi‐domain protein that functions in cell proliferation and movement [27](#feb412365-bib-0027){ref-type="ref"}. Furthermore, it is strongly expressed in various cancers including stomach carcinoma [28](#feb412365-bib-0028){ref-type="ref"}, [29](#feb412365-bib-0029){ref-type="ref"}. That mutation of *ACAN* occurs in stomach carcinoma has been shown by comprehensive whole‐genome and transcriptome sequencing analysis [30](#feb412365-bib-0030){ref-type="ref"}. *HOXC11* is considered to be a novel potential oncogene with altered expression in stomach carcinoma pathogenesis by association analysis with candidate gene strategy [31](#feb412365-bib-0031){ref-type="ref"}. *MMP11* is known a marker of tumor invasion and metastasis [32](#feb412365-bib-0032){ref-type="ref"}. Moreover, previous reports detected the expression level of *MMP11* by microarray analysis and found that it was elevated in stomach carcinoma patients and quantitative polymerase chain reaction analysis also confirmed its up‐regulated expression [32](#feb412365-bib-0032){ref-type="ref"}, [33](#feb412365-bib-0033){ref-type="ref"}. Herein, up‐regulated expression of *ADAM12*,*ACAN*,*HOXC11* and *MMP11* may be involved in the pathology of STAD. Interestingly, *MMP11* was significantly associated with STAD diagnoses.

Besides the above validated differentially expressed miRNAs, we also found two miRNAs (hsa‐miR‐196b and hsa‐miR‐135b) were also differentially expressed in STAD. Moreover, hsa‐miR‐196 and hsa‐miR‐135 covered the most downstream target genes in the regulatory network between differentially expressed miRNAs and target genes. It has been demonstrated that the expression level of hsa‐miR‐196b is significantly higher in stomach carcinoma [34](#feb412365-bib-0034){ref-type="ref"}, [35](#feb412365-bib-0035){ref-type="ref"}. Additionally, overexpression of hsa‐miR‐196b is linked to stomach carcinoma and may be considered as a stomach carcinoma marker [36](#feb412365-bib-0036){ref-type="ref"}, [37](#feb412365-bib-0037){ref-type="ref"}. It was demonstrated that hsa‐miR‐135b is up‐regulated in stomach carcinoma tissues [38](#feb412365-bib-0038){ref-type="ref"}, [39](#feb412365-bib-0039){ref-type="ref"}. Based on the results obtained in several studies, hsa‐miR‐135b is reported as a potential biomarker of the intestinal‐type of STAD [40](#feb412365-bib-0040){ref-type="ref"}, [41](#feb412365-bib-0041){ref-type="ref"}, [42](#feb412365-bib-0042){ref-type="ref"}, [43](#feb412365-bib-0043){ref-type="ref"}. In our study, hsa‐miR‐196b and hsa‐miR‐135b were also up‐regulated, which was in line with previous reports. Further qRT‐PCR validation experiments for hsa‐miR‐196b and hsa‐miR‐135b are needed.

There are limitations to our study. Firstly, target site information for miRNA--mRNA pairs is needed for validation of the miRNA--mRNA interaction. Secondly, RNA‐seq and miRNA‐seq are further needed to screen larger numbers of candidate miRNA and mRNA. Thirdly, a luciferase assay for direct verification of the identified miRNA--target interactions is needed in further studies.

Conclusions {#feb412365-sec-0017}
===========

All in all, we found four key differentially expressed miRNAs including hsa‐miR‐139‐5p, hsa‐miR‐145‐3p, hsa‐miR‐145‐5p and hsa‐miR‐490‐3p, four DEGs (*ADAM12*,*ACAN*,*HOXC11* and *MMP11*) and three related signaling pathways (calcium signaling pathway, bile secretion and gastric acid secretion) in STAD, which provide a novel field for understanding the pathological mechanism of STAD. In addition, hsa‐miR‐139‐5p, hsa‐miR‐145‐3p and *MMP11* have a potential diagnostic value for STAD.
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**Fig. S1.** Venn diagram of MTIs in the groups of miRTarBAse database *vs* miRWalk database.
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**Table S1.** The original miR--target interactions from the miRWalk database.
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**Table S2.** The original miR--target interactions from the miRTarBAse database.
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Click here for additional data file.
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